PubMed دسترسی آزاد

An Exploratory Analysis of Potential Core Targets and Signaling Pathways Linking Dexmedetomidine to Diabetes Insipidus: Integration of FAERS Pharmacovigilance Data, Network Toxicology and Clinical Transcriptomics.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

BACKGROUND: Dexmedetomidine is widely used for clinical sedation, while clinical data suggest a potential correlation between its administration and diabetes insipidus. This exploratory study aimed to characterize molecular correlates linking dexmedetomidine and diabetes insipidus via multiomics and pharmacovigilance analysis. METHODS: FAERS data (2004-2024) were mined for disproportionality analysis to screen suggestive association signals. Network toxicology predicted shared targets of dexmedetomidine and diabetes insipidus, followed by GO/KEGG enrichment, PPI network construction and molecular docking. Transcriptome sequencing of 10 treated patients preliminarily validated bioinformatic correlations. RESULTS: A strong suggestive association signal was detected (ROR=471.47). A total of 105 overlapping targets were screened, among which IL6, IL10, INS, IL1B, AKT1 and IFNG served as core correlated hub genes. Docking confirmed stable binding between dexmedetomidine and these proteins. Enrichment revealed enriched MAPK cascade, kinase activity and PI3K/AKT pathways, which may correlate with abnormal AQP2 function. Transcriptomics identified differential expression of inflammation-immune genes after infusion, consistent with predicted molecular correlations. CONCLUSION: This study combined FAERS pharmacovigilance analysis, network toxicology, molecular docking and transcriptome sequencing to explore potential mechanisms of dexmedetomidine-induced diabetes insipidus. FAERS data mining uncovered a robust adverse signal, indicating a strong correlation between dexmedetomidine and diabetes insipidus for clinical reference. Six hub genes and PI3K/AKT, MAPK pathways may be associated with this side effect. These findings facilitate high-risk population management and individualized sedation, and supply molecular candidates for future validation studies.

متن کامل اصلی

نسخه دارای مجوز در منبع علمی در دسترس است.

لینک مستقیم از metadata منبع گرفته شده و در تب جدید باز می‌شود.

باز کردن متن کامل

کلیدواژه‌ها

FAERS databasedexmedetomidinediabetes insipidusmolecular correlationnetwork toxicology
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

GLP-1R expression and dermatological diseases: a mendelian randomization and real-world study.

BACKGROUND: Although glucagon-like peptide-1 receptor (GLP-1R) is widely expressed in multiple tissues and organs including skin and subcutaneous tissue, with diverse physiological roles in metabolism and immunity, the potential causal association between GLP-1R expression and dermatological diseases remains unclear. METHODS: Available cis-expression quantitative trait loci (cis-eQTLs) were selected as genetic instruments for GLP-1R ex…

PubMed2026

Machine learning-driven pharmacovigilance of antidiabetic drugs: comparative reporting patterns and classification of serious adverse events.

PURPOSE: This study aims to evaluate the comparative adverse drug event (ADE) reporting patterns associated with antidiabetic drugs and develop machine learning (ML)-based classification models for the seriousness of reported ADEs. METHODS: We performed a retrospective analysis of 28,633 antidiabetic-related ADEs reported to the Korea Institute of Drug Safety and Management- Korea Adverse Event Reporting System database (KAERS DB 2505A…

PubMed2026

Artificial Intelligence Across the Pharmaceutical Life Cycle: Implications for Industry-Based Clinical Pharmacists.

Artificial intelligence (AI) is increasingly shaping the pharmaceutical industry. This ACCP commentary examines the implications of AI for industry-based clinical pharmacists across the pharmaceutical life cycle, including drug development, regulatory affairs, medical affairs, health economics and outcomes research, and pharmacovigilance. Artificial intelligence-enabled tools may support target identification, clinical trial design, re…

PubMed2026

FAERS-based pharmacovigilance study of sevoflurane-associated adverse events: A 20-year comprehensive analysis.

BACKGROUND: Sevoflurane, an ether-derived inhalational anesthetic widely used for general anesthesia, requires comprehensive safety evaluation. OBJECTIVES: This study aimed to identify sevoflurane-associated adverse events and detect unexpected safety signals using data from the FDA Adverse Event Reporting System (FAERS). METHODS: We analyzed FAERS data from the first quarter of 2004 through the first quarter of 2024, applying four dis…